The Oncology Institute Enrolls Nation’s First Two Patients in a Phase III Open-Label, Randomized Clinical Trial of Pirtobrutinib

The Oncology Institute, Inc. announced the enrollment of two of its patients as the first and second patients dosed in the United States in a Phase III open-label, randomized study of Pirtobrutinib versus Ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma .